<!DOCTYPE html>



<html lang="en">



	<meta charset="UTF-8">

	<meta name="viewport" content="width=device-width, initial-scale=1.0">

	<style>


    .node {

        stroke: #fff;

        stroke-width: 2px;

    }

    

    .link {

        stroke: #777;

        stroke-width: 2px;

    }



</style>

<body>

<a href="https://riskrunners.com">Home</a><br>




<a href="#risk_factors">Jump to Risk Factors</a><br>



<a href="#industry">Jump to Industries</a><br>


<a href="#exposure">Jump to Exposures</a><br>


<a href="#event_code">Jump to Event Codes</a><br>


<a href="#wiki">Jump to Wiki Summary</a><br><br>


    <script src="https://d3js.org/d3.v3.min.js"></script>

    <script>


// set a width and height for our SVG

var width = 3000,


    height = 3000;

    
// setup links

var links =     [
{source: "START_HERE", target: "1: following risk factors could", fill: "#7b68ee"},
{source: "1: following risk factors could", target: "1: Companys ", fill: "#7b68ee"},
{source: "1: Companys ", target: "1: financial position", fill: "#7b68ee"},
{source: "1: financial position", target: "1: operations", fill: "#7b68ee"},
{source: "1: following risk factors could", target: "3: future revenue growth", fill: "#654321"},
{source: "3: future revenue growth", target: "3: profitability", fill: "#654321"},
{source: "3: profitability", target: "3: dependent upon", fill: "#654321"},
{source: "3: dependent upon", target: "3: introduce new products on", fill: "#654321"},
{source: "3: introduce new products on", target: "3: timely basis", fill: "#654321"},
{source: "3: timely basis", target: "3: competitors product introductions", fill: "#654321"},
{source: "3: future revenue growth", target: "6: manufacture", fill: "#a50b5e"},
{source: "6: manufacture", target: "6: market new", fill: "#a50b5e"},
{source: "6: market new", target: "6: pharmaceutical products", fill: "#a50b5e"},
{source: "6: pharmaceutical products", target: "6: rigorous timeconsuming costly", fill: "#a50b5e"},
{source: "6: manufacture", target: "7: approvals on", fill: "#848482"},
{source: "7: approvals on", target: "7: timely basis", fill: "#848482"},
{source: "7: timely basis", target: "7: new generic products", fill: "#848482"},
{source: "7: approvals on", target: "10: may face immediate competition", fill: "#d2691e"},
{source: "10: may face immediate competition", target: "10: generic product into", fill: "#d2691e"},
{source: "10: may face immediate competition", target: "12: generic market entrants", fill: "#004225"},
{source: "12: generic market entrants", target: "12: generally", fill: "#004225"},
{source: "12: generally", target: "12: continued price", fill: "#004225"},
{source: "12: continued price", target: "12: margin erosion over", fill: "#004225"},
{source: "12: margin erosion over", target: "12: generic product", fill: "#004225"},
{source: "12: generic market entrants", target: "13: approved products may", fill: "#c08081"},
{source: "13: approved products may", target: "13: market acceptance", fill: "#c08081"},
{source: "13: market acceptance", target: "13: which could", fill: "#c08081"},
{source: "13: which could", target: "13: profitability financial", fill: "#c08081"},
{source: "13: profitability financial", target: "13: operations", fill: "#c08081"},
{source: "13: approved products may", target: "14: regulatory approvals", fill: "#addfad"},
{source: "14: regulatory approvals", target: "14: new pharmaceutical products generic", fill: "#addfad"},
{source: "14: new pharmaceutical products generic", target: "14: dependent upon market acceptance", fill: "#addfad"},
{source: "14: regulatory approvals", target: "15: acceptance", fill: "#e1a95f"},
{source: "15: acceptance", target: "15: availability", fill: "#e1a95f"},
{source: "15: availability", target: "15: alternative", fill: "#e1a95f"},
{source: "15: alternative", target: "15: competitors", fill: "#e1a95f"},
{source: "15: competitors", target: "15: effectively", fill: "#e1a95f"},
{source: "15: effectively", target: "15: retail level", fill: "#e1a95f"},
{source: "15: retail level", target: "15: products by government", fill: "#e1a95f"},
{source: "15: products by government", target: "15: private formularies", fill: "#e1a95f"},
{source: "15: private formularies", target: "15: to the Some ", fill: "#e1a95f"},
{source: "15: acceptance", target: "17: Additionally ", fill: "#df73ff"},
{source: "17: Additionally ", target: "17: utilization safety", fill: "#df73ff"},
{source: "17: utilization safety", target: "17: pharmaceutical", fill: "#df73ff"},
{source: "17: pharmaceutical", target: "17: conducted by", fill: "#df73ff"},
{source: "17: conducted by", target: "17: industry government agencies", fill: "#df73ff"},
{source: "17: Additionally ", target: "23: pharmaceutical", fill: "#6ca0dc"},
{source: "23: pharmaceutical", target: "23: significant", fill: "#6ca0dc"},
{source: "23: significant", target: "23: uncertainties", fill: "#6ca0dc"},
{source: "23: uncertainties", target: "23: regulations", fill: "#6ca0dc"},
{source: "23: pharmaceutical", target: "26: must comply with", fill: "#f88379"},
{source: "26: must comply with", target: "26: requirements with respect", fill: "#f88379"},
{source: "26: requirements with respect", target: "26: manufacture labeling sale distribution", fill: "#f88379"},
{source: "26: manufacture labeling sale distribution", target: "26: advertising", fill: "#f88379"},
{source: "26: advertising", target: "26: development", fill: "#f88379"},
{source: "26: development", target: "26: pharmaceutical", fill: "#f88379"},
{source: "26: must comply with", target: "29: Although ", fill: "#253529"},
{source: "29: Although ", target: "29: compliance history there", fill: "#253529"},
{source: "29: Although ", target: "31: new drug approval process", fill: "#f4c430"},
{source: "31: new drug approval process", target: "31: also regulates", fill: "#f4c430"},
{source: "31: also regulates", target: "31: facilities", fill: "#f4c430"},
{source: "31: facilities", target: "31: operational procedures", fill: "#f4c430"},
{source: "31: operational procedures", target: "31: manufacture", fill: "#f4c430"},
{source: "31: new drug approval process", target: "34: regulations", fill: "#c154c1"},
{source: "34: regulations", target: "34: enforcement action brought by", fill: "#c154c1"},
{source: "34: enforcement action brought by", target: "34: in an FDA ", fill: "#c154c1"},
{source: "34: in an FDA ", target: "34: which periodically", fill: "#c154c1"},
{source: "34: which periodically", target: "34: manufacturing facilities", fill: "#c154c1"},
{source: "34: manufacturing facilities", target: "34: compliance which could", fill: "#c154c1"},
{source: "34: compliance which could", target: "34: applications", fill: "#c154c1"},
{source: "34: applications", target: "34: facility", fill: "#c154c1"},
{source: "34: facility", target: "34: deficiencies", fill: "#c154c1"},
{source: "34: regulations", target: "51: These ", fill: "#4cbb17"},
{source: "51: These ", target: "51: undergo significant", fill: "#4cbb17"},
{source: "51: undergo significant", target: "51: consolidation", fill: "#4cbb17"},
{source: "51: These ", target: "58: inherent uncertainties involved", fill: "#a2a2d0"},
{source: "58: inherent uncertainties involved", target: "58: assumptions used", fill: "#a2a2d0"},
{source: "58: assumptions used", target: "58: preparation", fill: "#a2a2d0"},
{source: "58: preparation", target: "58: financial statements", fill: "#a2a2d0"},
{source: "58: financial statements", target: "58: accordance", fill: "#a2a2d0"},
{source: "58: accordance", target: "58: accounting principles generally accepted", fill: "#a2a2d0"},
{source: "58: accounting principles generally accepted", target: "58: United States ", fill: "#a2a2d0"},
{source: "58: United States ", target: "58: America GAAP", fill: "#a2a2d0"},
{source: "58: inherent uncertainties involved", target: "60: financial statements", fill: "#e97451"},
{source: "60: financial statements", target: "60: Securities and Exchange Commission SEC ", fill: "#e97451"},
{source: "60: Securities and Exchange Commission SEC ", target: "60: accordance with", fill: "#e97451"},
{source: "60: accordance with", target: "60: preparation", fill: "#e97451"},
{source: "60: financial statements", target: "67: electronic", fill: "#e25098"},
{source: "67: electronic", target: "67: Annual Reports ", fill: "#e25098"},
{source: "67: Annual Reports ", target: "67: Quarterly Reports ", fill: "#e25098"},
{source: "67: Quarterly Reports ", target: "67: Current Reports ", fill: "#e25098"},
{source: "67: Current Reports ", target: "67: amendments", fill: "#e25098"},
{source: "67: amendments", target: "67: Securities Exchange Act ", fill: "#e25098"},
{source: "67: Securities Exchange Act ", target: "67: reasonably", fill: "#e25098"},
{source: "67: reasonably", target: "67: electronically", fill: "#e25098"},
{source: "67: electronically", target: "67: to the SEC Our SEC ", fill: "#e25098"},
{source: "67: to the SEC Our SEC ", target: "67: also available through", fill: "#e25098"},
{source: "67: also available through", target: "67: website at www", fill: "#e25098"},
{source: "67: electronic", target: "START_HERE", fill: "#e25098"}]; 
    // create empty nodes array
    var nodes = {};
	var colorFill = [];
	
    // compute nodes from links data
    links.forEach(function(link) {
        link.source = nodes[link.source] ||
            (nodes[link.source] = {name: link.source});
        link.target = nodes[link.target] ||
            (nodes[link.target] = {name: link.target});
		colorFill.push({name: link.source.name, fill: link.fill });
		colorFill.push({name: link.target.name, fill: link.fill });
    });
	
	console.log(colorFill);


    // add a SVG to the body for our viz
    var svg=d3.select('body').append('svg')
        .attr("viewBox", "0 0 " + width + " " + height );

    // use the force
    var force = d3.layout.force()
		.charge(-5000)
		.gravity(0.3)
        .size([width, height])
        .nodes(d3.values(nodes))
        .links(links)
        .on("tick", tick)
        .linkDistance(200)
        .start();

    // add links
    var link = svg.selectAll('.link')
        .data(links)
        .enter().append('line')
        .attr('class', 'link'); 

    // add nodes
    var node = svg.selectAll('.node')
        .data(force.nodes())
        .enter().append('circle')
        .attr('class', 'node')
        .attr('r', width * 0.0035)
		.style("fill", function(d) {
									for (var i = 0; i < colorFill.length; i++) {
										//console.log(d.name);
										if(colorFill[i].name == d.name){
											console.log(colorFill[i].fill);
											return colorFill[i].fill;
										}
									} return "#555";
									
									});
	var label = svg.selectAll(null)
		.data(force.nodes())
		.enter()
		.append("text")
		.text(function (d) { return d.name; })
		.style("text-anchor", "middle")
		.style("fill", "#555")
		.style("font-family", "Arial")
		.style("font-size", 34);


    // what to do 
    function tick(e) {
        
        node.attr('cx', function(d) { return d.x = Math.max(6, Math.min(width - 6, d.x)); })
            .attr('cy', function(d) { return d.y = Math.max(6, Math.min(height - 6, d.y)); })
            .call(force.drag);
            
        link.attr('x1', function(d) { return d.source.x; })
            .attr('y1', function(d) { return d.source.y; })
            .attr('x2', function(d) { return d.target.x; })
            .attr('y2', function(d) { return d.target.y; });
		
		label.attr("x", function(d){ return d.x; })
             .attr("y", function (d) {return d.y - 10; });
        
    }
    
</script><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='industry'>Industries</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Advertising</td>
    </tr>
    <tr>
      <td>Health Care Facilities</td>
    </tr>
    <tr>
      <td>Automobile Manufacturers</td>
    </tr>
    <tr>
      <td>Motorcycle Manufacturers</td>
    </tr>
    <tr>
      <td>Independent Power Producers and Energy Traders</td>
    </tr>
    <tr>
      <td>Human Resource and Employment Services</td>
    </tr>
    <tr>
      <td>Electronic Equipment and Instruments</td>
    </tr>
    <tr>
      <td>Information Technology</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='exposure'>Exposures</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Military</td>
    </tr>
    <tr>
      <td>Regime</td>
    </tr>
    <tr>
      <td>Express intent</td>
    </tr>
    <tr>
      <td>Ease</td>
    </tr>
    <tr>
      <td>Provide</td>
    </tr>
    <tr>
      <td>Intelligence</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='event_code'>Event Codes</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Solicit support</td>
    </tr>
    <tr>
      <td>Vote</td>
    </tr>
    <tr>
      <td>Yield</td>
    </tr>
    <tr>
      <td>Force</td>
    </tr>
    <tr>
      <td>Reject</td>
    </tr>
    <tr>
      <td>Warn</td>
    </tr>
    <tr>
      <td>Yield to order</td>
    </tr>
    <tr>
      <td>Agree</td>
    </tr>
    <tr>
      <td>Grant</td>
    </tr>
    <tr>
      <td>Complain</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='wiki'>Wiki</th>
      <th>Wiki Summary</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Reliance_Retail">Reliance Retail</a></td>
      <td>Reliance Retail is an Indian retail company and a subsidiary of Reliance Industries Limited. Founded in 2006, it is the largest retailer in India in terms of revenue.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Arithmetic">Arithmetic</a></td>
      <td>Arithmetic (from Ancient Greek  ἀριθμός (arithmós) 'number', and  τική [τέχνη] (tikḗ [tékhnē]) 'art, craft') is an elementary part of mathematics that consists of the study of the properties of the traditional operations on numbers—addition, subtraction, multiplication, division, exponentiation, and extraction of roots. In the 19th century, Italian mathematician Giuseppe Peano formalized arithmetic with his Peano axioms, which are highly important to the field of mathematical logic today.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Emergency_operations_center">Emergency operations center</a></td>
      <td>An emergency operations center (EOC) is a central command and control facility responsible for carrying out the principles of emergency preparedness and emergency management, or disaster management functions at a strategic level during an emergency, and ensuring the continuity of operation of a company, political subdivision or other organization.\nAn EOC is responsible for strategic direction and operational decisions and does not normally directly control field assets, instead leaving tactical decisions to lower commands.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Operations_research">Operations research</a></td>
      <td>Operations research (British English: operational research), often shortened to the initialism OR, is a discipline that deals with the development and application of advanced analytical methods to improve decision-making. It is sometimes considered to be a subfield of mathematical sciences.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Shock_and_awe">Shock and awe</a></td>
      <td>Shock and awe (technically known as rapid dominance)  is a tactic based on the use of overwhelming power and spectacular displays of force to paralyze the enemy's perception of the battlefield and destroy their will to fight. Though the concept has a variety of historical precedents, the doctrine was explained by Harlan K. Ullman and James P. Wade in 1996 and was developed specifically for application by the US military by the National Defense University of the United States.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/ISA_230_Documentation">ISA 230 Documentation</a></td>
      <td>ISA 230 Audit Documentation is one of the International Standards on Auditing. It serves to direct the documentation of audit working papers in order to assist the audit planning and performance; the supervision and review of the audit work; and the recording of audit evidence resulting from the audit work in order to support the auditor's opinion.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Physical_inventory">Physical inventory</a></td>
      <td>Physical inventory is a process where a business physically counts its entire inventory.  A physical inventory may be mandated by financial accounting rules or the tax regulations to place an accurate value on the inventory, or the business may need to count inventory so component parts or raw materials can be restocked.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Northern_Fleet">Northern Fleet</a></td>
      <td>The Northern Fleet (Russian: Северный флот, Severnyy flot) is the fleet of the Russian Navy in the Arctic.According to the Russian ministry of defence: "The Northern Fleet dates its history back to a squadron created in 1733 to protect the territories of the Russian Empire, sea trade routes and fisheries in the White Sea near the coast of the Kola Peninsula. The order of the Commander-in-Chief of the Russian Navy of 25 May 2014 determined 1733 as the year of foundation of the Northern Fleet, and June 1 as its annual holiday".In its modern iteration, the Arctic Ocean Flotilla of the former Imperial Navy evolved into a full fleet of the Soviet Navy in 1933 as the Northern Flotilla.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Warehouse">Warehouse</a></td>
      <td>A warehouse is a building for storing goods. Warehouses are used by manufacturers, importers, exporters, wholesalers, transport businesses, customs, etc.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Russian_Navy">Russian Navy</a></td>
      <td>The Russian Navy (Russian: Военно-морской флот [ВМФ], romanized: Voyenno-morskoi flot [VMF], lit. '"Military Maritime Fleet"') is the naval arm of the Russian Armed Forces. It has existed in various forms since 1696, the present iteration of which was formed in January 1992 when it succeeded the Navy of the Commonwealth of Independent States (which had itself succeeded the Soviet Navy following the dissolution of the Soviet Union in late December 1991).</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Manufacturing">Manufacturing</a></td>
      <td>Manufacturing is the creation or production of goods with the help of equipment, labor, machines, tools, and chemical or biological processing or formulation. It is the essence of secondary sector of the economy.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Manufacture_royale">Manufacture royale</a></td>
      <td>Manufacture Royale is a Swiss luxury watch brand. Founded in the eighteenth century, the brand was revived in 2010.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Generic_trademark">Generic trademark</a></td>
      <td>A generic trademark, also known as a genericized trademark or proprietary eponym, is a trademark or brand name that, because of its popularity or significance, has become the generic term for, or synonymous with, a general class of products or services, usually against the intentions of the trademark's owner.\nA trademark is said to become genericized—or, informally, to have suffered genericide—when it begins as a distinctive product identifier but changes in meaning to become generic.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Generic_Product_Identifier">Generic Product Identifier</a></td>
      <td>The Generic Product Identifier (GPI) is a 14-character hierarchical classification system that identifies drugs from their primary therapeutic use down to the unique interchangeable product regardless of manufacturer or package size. The code consists of seven subsets, each providing increasingly more specific information about a drug available with a prescription in the United States.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Generic_brand">Generic brand</a></td>
      <td>Generic brands of consumer products (often supermarket goods) are distinguished by the absence of a brand name, instead identified solely by product characteristics and identified by plain, usually black-and-white packaging. Generally they imitate more expensive branded products, competing on price.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Accounting_standard">Accounting standard</a></td>
      <td>Publicly traded companies typically are subject to rigorous standards. Small and midsized businesses often follow more simplified standards, plus any specific disclosures required by their specific lenders and shareholders.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Sherlock_Automated_Design_Analysis">Sherlock Automated Design Analysis</a></td>
      <td>Sherlock Automated Design Analysis is a software tool developed by DfR Solutions for analyzing, grading, and certifying the expected reliability of products at the circuit card assembly level. Based on the science of Physics of Failure, Sherlock predicts failure mechanism-specific failure rates over time using a combination of finite element method and material properties to capture stress values and first order analytical equations to evaluate damage evolution.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Shadow_mask">Shadow mask</a></td>
      <td>The shadow mask is one of the two technologies used in the manufacture of cathode-ray tube (CRT) televisions and computer monitors which produce clear, focused color images.  The other approach is the aperture grille, better known by its trade name, Trinitron.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Pharmaceutical_industry">Pharmaceutical industry</a></td>
      <td>The pharmaceutical industry discovers, develops, produces, and markets drugs or pharmaceutical drugs for use as medications to be administered to patients (or self-administered), with the aim to cure them, vaccinate them, or alleviate symptoms.  Pharmaceutical companies may deal in generic or brand medications and medical devices.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Availability">Availability</a></td>
      <td>In reliability engineering, the term availability has the following meanings:\n\nThe degree to which a system, subsystem or equipment is in a specified operable and committable state at the start of a mission, when the mission is called for at an unknown, i.e. a random, time.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Latin_Extended_Additional">Latin Extended Additional</a></td>
      <td>Latin Extended Additional is a Unicode block.\nThe characters in this block are mostly precomposed combinations of Latin letters with one or more general diacritical marks.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Additionality">Additionality</a></td>
      <td>Additionality is the property of an activity being additional by adding something new to the context. It is a determination of whether an intervention has an effect when  compared to a baseline.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Additional_director_general_of_police">Additional director general of police</a></td>
      <td>Additional Director General of Police (ADGP) is an Indian Police Service rank. Though having the maximum possible 3-star police rank just like Director General of Police,  ADGP's are considered same to DGP's.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Pharmaceutical_manufacturing">Pharmaceutical manufacturing</a></td>
      <td>Pharmaceutical manufacturing is the process of industrial-scale synthesis of pharmaceutical drugs as part of the pharmaceutical industry.  The process of drug manufacturing can be broken down into a series of unit operations, such as milling, granulation, coating, tablet pressing, and others.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Radio_regulation">Radio regulation</a></td>
      <td>Radio regulation refers to the regulation and licensing of radio in international law, by individual governments, and by municipalities.\n\n\n== International regulation ==\nThe International Telecommunication Union (ITU) is a specialized agency of the United Nations (UN) that is responsible for issues that concern information and communication technologies.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Regulation_of_therapeutic_goods">Regulation of therapeutic goods</a></td>
      <td>The regulation of therapeutic goods, defined as drugs and therapeutic devices, varies by jurisdiction. In some countries, such as the United States, they are regulated at the national level by a single agency.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Compliance_(psychology)">Compliance (psychology)</a></td>
      <td>Compliance is a response—specifically, a submission—made in reaction to a request.  The request may be explicit (e.g., foot-in-the-door technique) or implicit (e.g., advertising).</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/List_of_Toyota_factories">List of Toyota factories</a></td>
      <td>This list comprises Toyota's manufacturing facilities worldwide, as well as others that are jointly owned by the company or run under a contract.\n\n\n== Toyota manufacturing facilities ==\n\n\n=== Asia ===\n\n\n==== Japan ====\nThere are a total of sixteen Toyota-owned factories in Japan.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Publix">Publix</a></td>
      <td>In public relations and communication science, publics are groups of individual people, and the public (a.k.a. the general public) is the totality of such groupings.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Website">Website</a></td>
      <td>A website (also written as web site) is a collection of web pages and related content that is identified by a common domain name and published on at least one web server. Examples of notable websites are Google, Facebook, Amazon, and Wikipedia.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Sample_preparation">Sample preparation</a></td>
      <td>In analytical chemistry, sample preparation (working-up) refers to the ways in which a sample is treated prior to its analyses. Preparation is a very important  step in most analytical techniques, because the techniques are often not responsive to the analyte in its in-situ form, or the results are distorted by interfering species.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Consolidated_financial_statement">Consolidated financial statement</a></td>
      <td>Consolidated financial statements are the "financial statements of a group in which the assets, liabilities, equity, income, expenses and cash flows of the parent company and its subsidiaries are presented as those of a single economic entity", according to International Accounting Standard 27 "Consolidated and separate financial statements", and International Financial Reporting Standard 10 "Consolidated financial statements".\n\n\n== Consolidated statement of financial position ==\nWhile preparing a consolidated financial statement, there are two basic procedures that need to be followed: first, cancel out all the items that are accounted as an asset in one company and a liability in another, and then add together all uncancelled items.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/United_States_securities_regulation">United States securities regulation</a></td>
      <td>Securities regulation in the United States is the field of U.S. law that covers transactions and other dealings with securities. The term is usually understood to include both federal and state-level regulation by governmental regulatory agencies, but sometimes may also encompass listing requirements of exchanges like the New York Stock Exchange and rules of self-regulatory organizations like the Financial Industry Regulatory Authority (FINRA).On the federal level, the primary securities regulator is the Securities and Exchange Commission (SEC).</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/STOCK_Act">STOCK Act</a></td>
      <td>The Stop Trading on Congressional Knowledge (STOCK) Act of 2012 (Pub.L. 112–105 (text) (PDF), S. 2038, 126 Stat. 291, enacted April 4, 2012) is an Act of Congress designed to combat insider trading.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Investment_Company_Act_of_1940">Investment Company Act of 1940</a></td>
      <td>The Investment Company Act of 1940 (commonly referred to as the '40 Act) is an act of Congress which regulates investment funds. It was passed as a United States Public Law (Pub.L. 76–768) on August 22, 1940, and is codified at 15 U.S.C. §§ 80a-1–80a-64.</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='risk_factors'>Risk Factors</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>HI TECH PHARMACAL CO INC      Item 1A Risk Factors        The <font color="blue">following risk factors could</font> have a material adverse effect on the     Company’s business, <font color="blue">financial position</font> or results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>These risk     <font color="blue">factors may</font> not include all of the <font color="blue">important factors</font> that could affect our     business or our industry or that could cause our <font color="blue">future financial</font> results to     <font color="blue">differ materially from historic</font> or expected results or cause the market     price of our <font color="blue">common stock</font> to fluctuate or decline</td>
    </tr>
    <tr>
      <td>Delays in New Product Introductions        Our <font color="blue">future revenue growth</font> and <font color="blue">profitability</font> are <font color="blue">dependent upon</font> our ability     to develop and <font color="blue">introduce new products on</font> a <font color="blue">timely basis</font> in relation to our     <font color="blue">competitors</font>’ product <font color="blue">introduction</font>s</td>
    </tr>
    <tr>
      <td>Our failure to do so <font color="blue">successfully could</font>     have a material adverse effect on our <font color="blue">financial position</font> and results of     <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>Many products require FDA <font color="blue">approval prior</font> to being marketed</td>
    </tr>
    <tr>
      <td>The process of     obtaining  FDA  approval  to  <font color="blue">manufacture</font>  and  <font color="blue">market new</font> and generic     <font color="blue"><font color="blue">pharmaceutical</font> products</font> is rigorous, time-consuming, costly and largely     unpredictable</td>
    </tr>
    <tr>
      <td>We may be unable to obtain requisite FDA <font color="blue">approvals on</font> a     <font color="blue">timely basis</font> for <font color="blue">new <font color="blue">generic product</font>s</font> that we may develop</td>
    </tr>
    <tr>
      <td>The timing and     cost  of  obtaining  FDA  <font color="blue">approvals could adversely affect</font> our product     <font color="blue">introduction</font> plans, <font color="blue">financial position</font> and results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>The ANDA <font color="blue">process often</font> results in the FDA <font color="blue">granting final approval</font> to a     number of ANDAs for a <font color="blue">given product</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">may face immediate competition</font> when     we introduce a <font color="blue"><font color="blue">generic product</font> into</font> the market</td>
    </tr>
    <tr>
      <td>These <font color="blue">circumstances could</font>     result  in <font color="blue">significant</font>ly lower prices, as well as reduced margins, for     <font color="blue"><font color="blue">generic product</font>s compared</font> to brand products</td>
    </tr>
    <tr>
      <td>New <font color="blue">generic market entrants</font>     <font color="blue">generally</font> cause <font color="blue">continued price</font> and <font color="blue">margin erosion over</font> the <font color="blue">generic product</font>     life cycle</td>
    </tr>
    <tr>
      <td>Approved Products May Not Achieve Expected Levels of Market Acceptance        Our <font color="blue">approved <font color="blue">products may</font></font> not achieve expected levels of <font color="blue">market <font color="blue">acceptance</font></font>,     <font color="blue">which could</font> have a material adverse effect on our <font color="blue">profitability</font>, financial     position  and  results  of  <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>Even if we were able to obtain     <font color="blue">regulatory approvals</font> of our new <font color="blue"><font color="blue">pharmaceutical</font> products</font>, generic or brand,     the success of those products is <font color="blue">dependent upon</font> <font color="blue">market <font color="blue">acceptance</font></font></td>
    </tr>
    <tr>
      <td>Levels of     <font color="blue">market <font color="blue">acceptance</font></font> for new products could be impacted by several factors,     including:           •   the <font color="blue">availability</font> of <font color="blue">alternative</font> products from our <font color="blue">competitors</font>           •   the price of our products relative to that of our <font color="blue">competitors</font>           •   the timing of our market entry           •   the ability of our customers to market our products <font color="blue">effectively</font> to the     <font color="blue">retail level</font>           •   the <font color="blue">acceptance</font> of our <font color="blue">products by government</font> and <font color="blue">private formularies</font>       Some of these factors are not within our control</td>
    </tr>
    <tr>
      <td>New <font color="blue">products may</font> not     achieve expected levels of <font color="blue">market <font color="blue">acceptance</font></font></td>
    </tr>
    <tr>
      <td>Additionally, continuing     studies of the proper utilization, safety and efficacy of <font color="blue">pharmaceutical</font>     products  are being <font color="blue">conducted by</font> the industry, government agencies and     others</td>
    </tr>
    <tr>
      <td>Such studies, which increasingly employ sophisticated methods and     <font color="blue">techniques</font>, can <font color="blue">call into question</font> the utilization, safety and efficacy of     <font color="blue">previously marketed products</font></td>
    </tr>
    <tr>
      <td>In some cases, these studies have resulted,     and may in the future result, in the <font color="blue">discontinuance</font> of <font color="blue">product marketing</font></td>
    </tr>
    <tr>
      <td>These situations, should they occur, could have a material adverse effect on     our <font color="blue">profitability</font>, <font color="blue">financial position</font> and results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td><font color="blue">Industry </font>is Highly Competitive        We <font color="blue">face competition from</font> other <font color="blue">pharmaceutical</font> <font color="blue">manufacture</font>rs that threatens     the commercial <font color="blue">acceptance</font> and pricing of our products, <font color="blue">which could</font> have a     material adverse effect on our business, <font color="blue">financial position</font> and results of     <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">competitors</font> may be able to develop products and <font color="blue">processes competitive</font>     with or superior to our own for many reasons, including that they may have:           •   <font color="blue">proprietary processes</font> or <font color="blue">delivery systems</font>           •   <font color="blue">larger research</font> and <font color="blue"><font color="blue">development</font> staffs</font>                                           10     ______________________________________________________________________         •   <font color="blue">larger sales</font> and <font color="blue">marketing staffs</font>           •   <font color="blue">larger production capabilities</font>           •   more products           •   more experience in developing new drugs and <font color="blue">greater financial</font>     resources       Each of these factors and others could have a material adverse effect on our     business, <font color="blue">financial position</font> and results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>Government Regulation        Because  the  <font color="blue">pharmaceutical</font>  industry  is  heavily regulated, we face     <font color="blue">significant</font> costs and <font color="blue">uncertainties</font> associated with our efforts to comply     with applicable <font color="blue">regulations</font></td>
    </tr>
    <tr>
      <td>Should we fail to comply, we could experience     material <font color="blue">adverse effects on</font> our business, <font color="blue">financial position</font> and results of     <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">pharmaceutical</font> industry is subject to <font color="blue">regulation by <font color="blue">various federal</font></font> and     state  <font color="blue">governmental authorities</font></td>
    </tr>
    <tr>
      <td>For instance, we <font color="blue">must comply with</font> FDA     <font color="blue">requirements with respect</font> to the <font color="blue">manufacture</font>, labeling, sale, distribution,     marketing,  <font color="blue">advertising</font>,  promotion  and <font color="blue">development</font> of <font color="blue">pharmaceutical</font>     products</td>
    </tr>
    <tr>
      <td>Failure to comply with FDA and other governmental <font color="blue">regulations</font> can     result in fines, disgorgement, unanticipated compliance <font color="blue">expenditures</font>, recall     or seizure of products, total or <font color="blue">partial suspension</font> of production and/or     distribution, suspension of FDA’s review of ANDAs, <font color="blue">enforcement actions</font>,     <font color="blue">injunctions</font> and <font color="blue">criminal prosecution</font></td>
    </tr>
    <tr>
      <td>Under <font color="blue">certain circumstances</font>, the FDA     also has the authority to <font color="blue">revoke previously granted drug approvals</font></td>
    </tr>
    <tr>
      <td><font color="blue">Although     </font>we have internal regulatory compliance programs and policies and have had a     favorable compliance history, there is no guarantee that we may not be     deemed to be deficient in some manner in the future</td>
    </tr>
    <tr>
      <td>If we were deemed to be     deficient in any <font color="blue">significant</font> way, it could have a material adverse effect on     our business, <font color="blue">financial position</font> and results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>In addition to the <font color="blue">new drug approval process</font>, the FDA <font color="blue">also regulates</font> the     <font color="blue">facilities</font>  and  <font color="blue">operational procedures</font> that we use to <font color="blue">manufacture</font> our     products</td>
    </tr>
    <tr>
      <td>We  <font color="blue">must register</font> our <font color="blue">facilities</font> with the FDA All products     <font color="blue">manufacture</font>d in those <font color="blue">facilities</font> must be made in a <font color="blue">manner consistent with</font>     current  Good  Manufacturing  Practices (“cGMP”)</td>
    </tr>
    <tr>
      <td><font color="blue">Compliance </font><font color="blue">with cGMP</font>     <font color="blue">regulations</font> requires substantial <font color="blue">expenditures</font> of time, money and effort in     such  <font color="blue">areas as production</font> and <font color="blue">quality control</font> to ensure full technical     compliance</td>
    </tr>
    <tr>
      <td>Failure to comply <font color="blue">with cGMP</font> <font color="blue">regulations</font> could result in an     <font color="blue">enforcement action brought by</font> the FDA, <font color="blue">which <font color="blue">periodically</font></font> inspects our     <font color="blue">manufacturing</font> <font color="blue">facilities</font> for compliance, <font color="blue">which could</font> include withholding the     approval  of  ANDAs  or  other  product  <font color="blue">applications</font> of a <font color="blue">facility</font> if     <font color="blue">deficiencies</font> are found at that <font color="blue">facility</font></td>
    </tr>
    <tr>
      <td>FDA approval to <font color="blue">manufacture</font> a drug     is site-specific</td>
    </tr>
    <tr>
      <td><font color="blue">If the FDA </font>would cause our <font color="blue">manufacturing</font> <font color="blue">facilities</font> to     cease or <font color="blue">limit production</font>, our business could be <font color="blue">adversely affected</font></td>
    </tr>
    <tr>
      <td><font color="blue">Delay     </font>and cost in obtaining FDA approval to <font color="blue">manufacture</font> at a different <font color="blue">facility</font>     also  could  have a material adverse effect on our business, financial     position and results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>We are subject, as are <font color="blue">generally</font> all <font color="blue">manufacture</font>rs, to <font color="blue">various federal</font>,     state and <font color="blue">local laws</font> of general applicability, such as laws regulating     working  <font color="blue">conditions</font>,  as  well  as  <font color="blue">environment</font>al  <font color="blue">protection laws</font> and     <font color="blue">regulations</font>, including those governing the discharge of <font color="blue">materials into</font> the     <font color="blue">environment</font></td>
    </tr>
    <tr>
      <td>Although we have not incurred <font color="blue">significant</font> costs associated with     complying with such <font color="blue">environment</font>al provisions in the past, if changes to such     <font color="blue">environment</font>al provisions are made in the future that require <font color="blue">significant</font>     changes  in  our  <font color="blue">operations</font>  or  if  we engage in the <font color="blue">development</font> and     <font color="blue">manufacturing</font> of new products requiring new or different <font color="blue">environment</font>al     controls, we may be required to expend <font color="blue">significant</font> funds</td>
    </tr>
    <tr>
      <td>Such changes could     have a material adverse effect on our business, <font color="blue">financial position</font> and     results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>Limited Number of Major Customers        Our top 5 customers, based on sales, accounted for 55prca of our <font color="blue">total sales</font>     for fiscal 2006</td>
    </tr>
    <tr>
      <td>Any <font color="blue">significant</font> reduction of business with any of our top 5     <font color="blue">customers could</font> have a material adverse effect on our business, financial     position and results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>Third Party Suppliers        Active <font color="blue">pharmaceutical</font> ingredients, packaging components, and other materials     and supplies that we use in our <font color="blue">pharmaceutical</font> <font color="blue">manufacturing</font> <font color="blue">operations</font>, as     <font color="blue">well as certain</font> finished products, are <font color="blue">generally</font> available and purchased     from  many  <font color="blue">different foreign</font> and <font color="blue">domestic suppliers</font></td>
    </tr>
    <tr>
      <td>Additionally, we     maintain <font color="blue">sufficient raw materials inventory</font>, and in <font color="blue">certain cases</font> where we     have <font color="blue">listed only one supplier</font> in our <font color="blue">applications</font> with the FDA, we have     received FDA approval to use                                           11     ______________________________________________________________________       <font color="blue">alternative</font> suppliers should the need arise</td>
    </tr>
    <tr>
      <td>However, there is no guarantee     that we <font color="blue">will always</font> have timely and <font color="blue">sufficient access</font> to a <font color="blue">critical raw</font>     material or finished product</td>
    </tr>
    <tr>
      <td>A <font color="blue">prolonged interruption</font> in the supply of a     single-sourced  active  ingredient or finished <font color="blue">product could</font> cause our     <font color="blue">financial position</font> and results of <font color="blue">operations</font> to be <font color="blue">materially adversely</font>     affected</td>
    </tr>
    <tr>
      <td>Limited Number of Manufacturing Facilities        Our <font color="blue">generic product</font>s and some of our <font color="blue">branded products</font> are produced at our     two <font color="blue">manufacturing</font> <font color="blue">facilities</font> located at one site</td>
    </tr>
    <tr>
      <td>A <font color="blue">significant</font> disruption     at these <font color="blue">facilities</font>, even on a short-term basis, could impair our ability to     produce and <font color="blue">ship products</font> to the <font color="blue">market on</font> a <font color="blue">timely basis</font>, <font color="blue">which could</font> have     a material adverse effect on our business, <font color="blue">financial position</font> and results of     <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>Consolidation of Customers        A <font color="blue">significant</font> amount of our sales are made to a <font color="blue">relatively</font> small number of     drug wholesalers, retail drug chains, managed care purchasing organizations,     mail order pharmacies and hospitals</td>
    </tr>
    <tr>
      <td>These <font color="blue">customers represent</font> an essential     part of the <font color="blue">distribution chain</font> of generic <font color="blue"><font color="blue">pharmaceutical</font> products</font></td>
    </tr>
    <tr>
      <td><font color="blue">These     </font>customers  have  undergone, and are continuing to undergo, <font color="blue">significant</font>     <font color="blue">consolidation</font></td>
    </tr>
    <tr>
      <td>This  <font color="blue">consolidation</font> may result in these <font color="blue">groups gaining</font>     <font color="blue">additional purchasing leverage</font> and <font color="blue">consequently increasing</font> the product     <font color="blue">pricing pressures facing</font> our business</td>
    </tr>
    <tr>
      <td>Additionally, the emergence of large     buying groups <font color="blue">representing</font> <font color="blue">independent</font> retail pharmacies and the prevalence     and  influence  of <font color="blue">managed care organizations</font> and similar <font color="blue">institutions</font>     <font color="blue">potentially enable</font> those groups to attempt to <font color="blue">extract price discounts on</font> our     products</td>
    </tr>
    <tr>
      <td>The result of these <font color="blue">development</font>s may have a material adverse     effect on our business, <font color="blue">financial position</font> and results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>Indemnification Obligations        In the normal course of business, we <font color="blue">periodically</font> enter into <font color="blue">employment</font>,     legal <font color="blue">settlements</font>, and other <font color="blue">agreements which incorporate indemnification</font>     provisions</td>
    </tr>
    <tr>
      <td>We maintain <font color="blue">insurance coverage which</font> we believe will <font color="blue">effectively</font>     mitigate our <font color="blue">obligations under</font> these <font color="blue">indemnification provisions</font></td>
    </tr>
    <tr>
      <td>However,     should our <font color="blue">obligation under</font> an <font color="blue">indemnification provision exceed</font> our coverage     or <font color="blue">should coverage</font> be denied, it could have a material adverse effect on our     business, <font color="blue">financial position</font> and results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>Uncertainties of <font color="blue">Estimates </font>and Assumptions        There  are inherent <font color="blue">uncertainties</font> involved in estimates, judgments and     <font color="blue"><font color="blue">assumptions</font> used</font> in the <font color="blue">preparation</font> of <font color="blue">financial statements</font> in <font color="blue">accordance</font>     with  accounting principles <font color="blue">generally</font> accepted in the <font color="blue">United States </font>of     America (“GAAP”)</td>
    </tr>
    <tr>
      <td>Any changes in estimates, judgments and <font color="blue"><font color="blue">assumptions</font> used</font>     could have a material adverse effect on our business, <font color="blue">financial position</font> and     results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">financial statements</font> included in the periodic reports we file with the     Securities and Exchange Commission (“SEC”) are prepared in <font color="blue">accordance</font> with     GAAP  The <font color="blue">preparation</font> of <font color="blue">financial statements</font> in <font color="blue">accordance</font> with GAAP     involves making estimates of expenses and income</td>
    </tr>
    <tr>
      <td>This includes, but is not     limited to, estimates, judgments and <font color="blue"><font color="blue">assumptions</font> used</font> in the adoption of the     provisions of SFAS Nodtta 144, <font color="blue">Accounting for the Impairment or Disposal </font>of     Long-Lived Assets and SFAS Nodtta 123, as amended, Accounting for Stock-Based     Compensation</td>
    </tr>
    <tr>
      <td>Estimates, judgments and <font color="blue">assumptions</font> are inherently subject to     change in the future, and any such changes could result in <font color="blue">corresponding</font>     changes  to the amounts of assets, liabilities, revenues, expenses and     income</td>
    </tr>
    <tr>
      <td>Any  such changes could have a material adverse effect on our     business, <font color="blue">financial position</font> and results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td><font color="blue">Website Access to Filings </font>with the Securities and Exchange Commission        Additional information about the Company is <font color="blue">available on</font> our <font color="blue">website at</font>     www</td>
    </tr>
    <tr>
      <td>All of our <font color="blue">electronic</font> filings with the SEC including     <font color="blue">Annual Reports </font>on Form 10-K, <font color="blue">Quarterly Reports </font>on Form 10-Q, <font color="blue">Current Reports     </font>on Form 8-K and any <font color="blue">amendments</font> to these reports filed or furnished pursuant     to  Section 13(a) or 15(d) of the <font color="blue">Securities Exchange Act </font>of 1934, are     <font color="blue">available on</font> our website free of charge as soon as <font color="blue">reasonably</font> practicable     after they are <font color="blue">electronic</font>ally filed with and furnished <font color="blue">to the SEC Our SEC     </font>filings  are  <font color="blue">also available through</font> the SEC’s <font color="blue">website at</font> www</td>
    </tr>
    <tr>
      <td><font color="blue">Information </font><font color="blue">contained on</font> our website is not <font color="blue">incorporated by reference</font> in the     Annual  Report  on Form 10-K and shall not be deemed “filed” under the     <font color="blue">Securities Exchange Act </font>of 1934</td>
    </tr>
  </tbody>
</table>